机构：[1]Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510030, China中山大学附属第二医院[2]College of Pharmacy, Jinan University, Guangzhou 510632, China[3]International Cooperative Laboratory of Traditional Chinese Medicine Modernization & Innovative Drug Development of Chinese Ministry of Education (MOE), Jinan University, Guangzhou 510632, China[4]Guangzhou Huabo Biopharmaceutical Research Institute, Guangzhou 510010, China[5]Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics & Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510030, China中山大学附属第二医院[6]Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510030, China中山大学附属第二医院[7]Dongguan Institute of Jinan University, Dongguan 523808, China
Aim: To evaluate the cost-effectiveness of ribociclib plus fulvestrant versus fulvestrant in hormone receptor-positive/human EGF receptor 2-negative advanced breast cancer. Materials & methods: A three-state Markov model was developed to evaluate the costs and effectiveness over 10 years. Direct costs and utility values were obtained from previously published studies. We calculated incremental cost-effectiveness ratio to evaluate the cost-effectiveness at a willingness-to-pay threshold of $150,000 per additional quality-adjusted life year. Results: The incremental cost-effectiveness ratio was $1,073,526 per quality-adjusted life year of ribociclib plus fulvestrant versus fulvestrant. Conclusions: Ribociclib plus fulvestrant is not cost-effective versus fulvestrant in the treatment of advanced hormone receptor-positive/human EGF receptor 2-negative breast cancer. When ribociclib is at 10% of the full price, ribociclib plus fulvestrant could be cost-effective.
第一作者机构：[1]Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510030, China
共同第一作者：
通讯作者：
通讯机构：[2]College of Pharmacy, Jinan University, Guangzhou 510632, China[3]International Cooperative Laboratory of Traditional Chinese Medicine Modernization & Innovative Drug Development of Chinese Ministry of Education (MOE), Jinan University, Guangzhou 510632, China[7]Dongguan Institute of Jinan University, Dongguan 523808, China
推荐引用方式(GB/T 7714)：
Jiang Wei,He Zhichao,Zhang Tiantian,et al.Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.[J].IMMUNOTHERAPY.2021,13(8):661-668.doi:10.2217/imt-2020-0237.
APA：
Jiang Wei,He Zhichao,Zhang Tiantian,Guo Chongchong,Zhao Jianli...&Jiang Jie.(2021).Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer..IMMUNOTHERAPY,13,(8)
MLA：
Jiang Wei,et al."Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.".IMMUNOTHERAPY 13..8(2021):661-668
